Tim M. Mayleben
2021 - Landos Biopharma
In 2021, Tim M. Mayleben earned a total compensation of $1.1M as President, Chief Executive Officer and Director at Landos Biopharma.
Compensation breakdown
| Option Awards | $1,020,375 |
|---|---|
| Salary | $79,905 |
| Other | $33,769 |
| Total | $1,134,049 |
Mayleben received $1M in option awards, accounting for 90% of the total pay in 2021.
Mayleben also received $79.9K in salary and $33.8K in other compensation.
Rankings
In 2021, Tim M. Mayleben's compensation ranked 8,360th out of 12,415 executives tracked by ExecPay. In other words, Mayleben earned more than 32.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,360 out of 12,415 | 33rd |
Division Manufacturing | 3,702 out of 5,508 | 33rd |
Major group Chemicals And Allied Products | 1,647 out of 2,378 | 31st |
Industry group Drugs | 1,465 out of 2,099 | 30th |
Industry Pharmaceutical Preparations | 1,091 out of 1,549 | 30th |
Source: SEC filing on April 28, 2022.
Mayleben's colleagues
We found four more compensation records of executives who worked with Tim M. Mayleben at Landos Biopharma in 2021.
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019